Highs, lows of psychedelics research wrapped in first-time UCSF trial


Psychedelic drug research faces stigma, bias and basic research questions, let alone regulatory and business model concerns.

Previous Tivity Health CEO to be paid more than $30 million following deal to go private
Next Q&A: Philadelphia-based American Cancer Society CEO Karen Knudsen on her 'incredible' first year